

U.S. NUCLEAR REGULATORY COMMISSION

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated <b>November 10, 2015,</b>
1. Porter Regional Hospital	3. License No. 13-17073-01 is amended in its entirety to read as follows:
2. 85 East U.S. Highway 6 Valparaiso, Indiana 46383	4. Expiration Date: November 30, 2023
	5. Docket No. 030-12150 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies
D. Iridium-192 permitted by 10 CFR 35.400	D. Sealed sources (Best Medical International, Inc., Model 81-01)	D. 2 curies
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed sources (Bard Brachytherapy, Inc., Model STM 1251)	E. 2 curies
F. Yttrium-90 permitted by 10 CFR 35.1000	F. Sealed sources (Sirtex Medical Limited SIR-Spheres® microspheres)	F. 2 curies

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. through E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
  - F. For medical use as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
13-17073-01

Docket or Reference No.  
030-12150

Amendment No. 48

CONDITIONS

10. A. Licensed material in Subitems 6.A. through 6.F. may be used at the licensee's facilities located at 85 East U.S. Highway 6, Valparaiso, Indiana.
- B. Licensed material in Subitems 6.A. and 6.B. may be used at the licensee's facilities located at 1505 South Calumet, Chesterton, Indiana and at Porter Physician Services LLC d/b/a Porter Physician Group, Northwest Indiana Cardiovascular Physicians, 2000 Roosevelt Road, Valparaiso, Indiana.
11. The Radiation Safety Officer (RSO) for this license is James M. Forde, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

Authorized User

Material and Use

Amjad Alkadri, M.D.

10 CFR 35.100, 35.200, 35.300, and 35.1000 (limited to yttrium-90 as SIR-Spheres®).

Keith Atassi, M.D.

10 CFR 35.200.

Maximo V. Bleza, D.O.

10 CFR 35.100, 35.200, and 35.300.

John A. Forchetti, M.D.

10 CFR 35.100 and 35.200.

James M. Forde, M.D.

10 CFR 35.100, 35.200, and 35.300.

Jeffrey M. Huth, M.D.

10 CFR 35.100 and 35.200.

Anil Kothari, M.D.

10 CFR 35.100, 35.200 and 35.300 limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.

Esther Lee, M.D.

10 CFR 35.100, 35.200, and 35.300 limited to the oral administration of sodium iodide I-131.

Hector J. Marchand, M.D.

10 CFR 35.200.

Vivek Mishra, M.D.

10 CFR 35.100, 35.200, and 35.300 limited to the oral administration of sodium iodide I-131, and 35.1000 limited to yttrium-90 as SIR-Spheres®.

Jeffrey Jon Quackenbush, M.D.

10 CFR 35.300 and 35.400.

Koppolu P. Sarma, M.D.

10 CFR 35.400.

Sandeep Sehgal, M.D.

10 CFR 35.200.

Michael Wheat, M.D.

10 CFR 35.200.

Omar Barakat, M.D.

10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide I-131.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.

13-17073-01

Docket or Reference No.

030-12150

Amendment No. 48

Authorized User

Jay D. Shah, M.D.

Steven L. Hossler, M.D.

**Akram Kholoki, M.D.**Material and Use

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

**10 CFR 35.100 and 35.200.**

13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Materials."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 21, 2013 (ML13183A468, excluding delegation of authority for A. Devata); and
- B. Letter dated August 4, 2015 (ML15224B609).

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date

NOV 25 2015

By

Sara A. Forster, M.S.  
Materials Licensing Branch  
Region III